BRPI1010764A2 - "sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo" - Google Patents

"sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo"

Info

Publication number
BRPI1010764A2
BRPI1010764A2 BRPI1010764A BRPI1010764A BRPI1010764A2 BR PI1010764 A2 BRPI1010764 A2 BR PI1010764A2 BR PI1010764 A BRPI1010764 A BR PI1010764A BR PI1010764 A BRPI1010764 A BR PI1010764A BR PI1010764 A2 BRPI1010764 A2 BR PI1010764A2
Authority
BR
Brazil
Prior art keywords
pyrazolazo
azo
salts
substituted
preparation
Prior art date
Application number
BRPI1010764A
Other languages
English (en)
Inventor
Hejun Lü
Hongbo Fei
Peng Cho Tang
Yiqian Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai Hengrui Pharm Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BRPI1010764A2 publication Critical patent/BRPI1010764A2/pt
Publication of BRPI1010764B1 publication Critical patent/BRPI1010764B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1010764A 2009-06-11 2010-05-28 sais farmaceuticamente aceitáveis de derivados de pirazolon-azo biciclo substituído, seu uso e seu processo de preparação, composição farmacêutica e seu processo de preparação BRPI1010764B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100529461A CN101921232A (zh) 2009-06-11 2009-06-11 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
PCT/CN2010/000760 WO2010142137A1 (zh) 2009-06-11 2010-05-28 双环取代吡唑酮偶氮类衍生物的盐，及其制备方法和应用

Publications (2)

Publication Number Publication Date
BRPI1010764A2 true BRPI1010764A2 (pt) 2016-03-22
BRPI1010764B1 BRPI1010764B1 (pt) 2020-04-07

Family

ID=43308392

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010764A BRPI1010764B1 (pt) 2009-06-11 2010-05-28 sais farmaceuticamente aceitáveis de derivados de pirazolon-azo biciclo substituído, seu uso e seu processo de preparação, composição farmacêutica e seu processo de preparação

Country Status (18)

Country Link
US (2) US8642637B2 (pt)
EP (1) EP2441457B1 (pt)
JP (1) JP5821079B2 (pt)
KR (1) KR101738181B1 (pt)
CN (2) CN101921232A (pt)
AU (1) AU2010258027B2 (pt)
BR (1) BRPI1010764B1 (pt)
CA (1) CA2762916C (pt)
DK (1) DK2441457T3 (pt)
ES (1) ES2452039T3 (pt)
HK (1) HK1154503A1 (pt)
MX (1) MX2011012639A (pt)
PL (1) PL2441457T3 (pt)
PT (1) PT2441457E (pt)
RU (1) RU2538977C2 (pt)
UA (1) UA107353C2 (pt)
WO (1) WO2010142137A1 (pt)
ZA (1) ZA201108249B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921232A (zh) * 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
CN103910718B (zh) * 2013-01-08 2018-08-14 齐鲁制药有限公司 双环取代的吡唑酮偶氮类化合物、其制备方法和用途
CN106146330B (zh) * 2015-04-21 2018-04-06 江苏威凯尔医药科技有限公司 一种制备艾曲波帕中间体的方法
WO2017042839A1 (en) * 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
CN107249585B (zh) * 2016-01-22 2020-12-08 江苏恒瑞医药股份有限公司 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法
CN107870217B (zh) * 2016-09-26 2022-03-04 齐鲁制药有限公司 艾曲波帕中间体ⅰ有关物质的检测方法
TWI762556B (zh) * 2017-01-19 2022-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種雙環取代吡唑酮偶氮類衍生物的製備方法及其中間體
CN110028497B (zh) * 2018-01-11 2020-11-17 江苏恒瑞医药股份有限公司 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法
JP2022517211A (ja) * 2019-01-08 2022-03-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 二環式置換ピラゾロンアゾ誘導体の投与レジメン
TW202302090A (zh) * 2021-04-30 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 血小板生成素受體激動劑的給藥方案
WO2023143364A1 (zh) * 2022-01-25 2023-08-03 江苏恒瑞医药股份有限公司 一种血小板生成素受体激动剂的给药方案

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1732900A (en) 1998-11-17 2000-06-05 Ligand Pharmaceuticals Incorporated Methods of treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CA2380206A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
DE60025632T2 (de) 1999-09-10 2006-08-10 Smithkline Beecham Corp. Thrombopoietin-mimetika
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2275567T3 (es) 1999-12-06 2007-06-16 Smithkline Beecham Corporation Mimeticos de4 trombopoietina.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
EP1556059A4 (en) * 2002-06-06 2010-06-30 Smithkline Beecham MIMETICS OF THROMBOPOIETINE
MXPA06007255A (es) 2003-12-26 2006-08-18 Allergan Inc Oximas de chalcona disubstituidas que tienen actividad antagonista de los receptores retinoides rar?.
JP2009519352A (ja) * 2005-11-23 2009-05-14 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性調節化合物および方法
WO2008070583A2 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
CN101481352A (zh) * 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
MX2011012639A (es) 2011-12-14
ZA201108249B (en) 2012-07-25
RU2538977C2 (ru) 2015-01-10
CN101921232A (zh) 2010-12-22
EP2441457B1 (en) 2014-01-01
AU2010258027A1 (en) 2011-12-22
CA2762916A1 (en) 2010-12-16
KR20120028334A (ko) 2012-03-22
UA107353C2 (en) 2014-12-25
US20120164102A1 (en) 2012-06-28
KR101738181B1 (ko) 2017-05-19
PL2441457T3 (pl) 2014-06-30
CN102159217B (zh) 2012-10-03
PT2441457E (pt) 2014-03-20
US9120762B2 (en) 2015-09-01
WO2010142137A1 (zh) 2010-12-16
RU2011153934A (ru) 2013-07-20
HK1154503A1 (en) 2012-04-27
CA2762916C (en) 2018-06-12
EP2441457A1 (en) 2012-04-18
CN102159217A (zh) 2011-08-17
BRPI1010764B1 (pt) 2020-04-07
DK2441457T3 (en) 2014-03-10
JP5821079B2 (ja) 2015-11-24
ES2452039T3 (es) 2014-03-31
US20140140953A1 (en) 2014-05-22
AU2010258027B2 (en) 2015-01-29
JP2012529442A (ja) 2012-11-22
EP2441457A4 (en) 2012-10-31
US8642637B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
BRPI1010764A2 (pt) "sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo"
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
SMT201400055B (it) Composti di tioacetato, composizioni e metodi d'uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI0812317A2 (pt) Sais de ácido etilenodiamina dissuccínico, composição contendo os ditos sais, uso e método de preparação destes.
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06T Formal requirements before examination
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2010, OBSERVADAS AS CONDICOES LEGAIS.